REAC technology and hyaluron synthase 2, an interesting network to slow down stem cell senescence.

Sci Rep

National Institute of Biostructures and Biosystems at the Department of Experimental, Diagnostic and Specialty Medicine, S. Orsola - Malpighi Hospital, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy.

Published: June 2016

Hyaluronic acid (HA) plays a fundamental role in cell polarity and hydrodynamic processes, affording significant modulation of proliferation, migration, morphogenesis and senescence, with deep implication in the ability of stem cells to execute their differentiating plans. The Radio Electric Asymmetric Conveyer (REAC) technology is aimed to optimize the ions fluxes at the molecular level in order to optimize the molecular mechanisms driving cellular asymmetry and polarization. Here, we show that treatment with 4-methylumbelliferone (4-MU), a potent repressor of type 2 HA synthase and endogenous HA synthesis, dramatically antagonized the ability of REAC to recover the gene and protein expression of Bmi1, Oct4, Sox2, and Nanog in ADhMSCs that had been made senescent by prolonged culture up to the 30(th) passage. In senescent ADhMSCs, 4-MU also counteracted the REAC ability to rescue the gene expression of TERT, and the associated resumption of telomerase activity. Hence, the anti-senescence action of REAC is largely dependent upon the availability of endogenous HA synthesis. Endogenous HA and HA-binding proteins with REAC technology create an interesting network that acts on the modulation of cell polarity and intracellular environment. This suggests that REAC technology is effective on an intracellular niche level of stem cell regulation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919615PMC
http://dx.doi.org/10.1038/srep28682DOI Listing

Publication Analysis

Top Keywords

reac technology
16
interesting network
8
stem cell
8
cell polarity
8
endogenous synthesis
8
reac
7
technology hyaluron
4
hyaluron synthase
4
synthase interesting
4
network slow
4

Similar Publications

An 88-year-old woman presented with a longstanding history of dizziness, tremors, and progressive mental and physical decline, significantly impairing her mobility and autonomy. Recently discharged from an ICU, the patient required extensive support for daily activities. Diagnostic evaluations, including EEG and analysis, revealed irregular frequency peaks and altered cortical activity, particularly in the frontal and prefrontal regions.

View Article and Find Full Text PDF

This post-market clinical follow-up (PMCF) study evaluates the clinical effectiveness and safety of the external radio electric reprogramming for atrial fibrillation (EX-RER AF) protocol, a non-invasive regenerative medicine approach utilizing radio electric asymmetric conveyer (REAC) technology for managing paroxysmal atrial fibrillation (PAF). Administered with the REAC BENE mod 110 device (ASMED, Scandicci, Italy), the treatment involves a standardized procedure, with the asymmetric conveyor probe (ACP) positioned in the precordial area and fixed, unmodifiable parameters ensuring consistency and reproducibility. During a 36-month post-market clinical follow-up (PMCF), 20 patients with prior diagnoses of PAF underwent the protocol.

View Article and Find Full Text PDF

This case report explores the use of radio electric asymmetric conveyor (REAC) technology for chronic pain management, functional limitations, and metabolic dysfunction in a 67-year-old female with rheumatoid arthritis, advanced lipedema, and fibromyalgia. The patient underwent three REAC protocols: Anti-cellulite treatment (ACT), circulatory optimization (CO), and metabolic optimization (MO), each targeting distinct pathophysiological aspects. The ACT protocol primarily addressed chronic inflammation contributing to pain and tissue dysfunction associated with lipedema.

View Article and Find Full Text PDF

This case report presents the use of radio electric asymmetric conveyer (REAC) neuroregenerative (RGN-N) therapy in a pediatric patient with adrenoleukodystrophy (ALD), a progressive neurodegenerative disorder with limited therapeutic options. The patient underwent three REAC RGN-N treatment cycles, each lasting 72 hours, with approximately 6-7 hours of daily sessions. An asymmetric conveyor probe (ACP) was positioned along the spine to channel the interaction of the emitted radio electric field with cellular electro-metabolic alterations, promoting progressive bioelectrical restoration.

View Article and Find Full Text PDF

This case report describes the treatment of a 9-year-old boy with advanced adrenoleukodystrophy (ALD) who received radioelectric asymmetric conveyer (REAC) neuro-regenerative (RGN-N) therapy after hematopoietic stem cell transplantation (HSCT) failed to produce therapeutic benefits. ALD is a devastating neurodegenerative disorder for which limited treatment options exist, and interventions are often ineffective in advanced cases. Post-transplant, the patient's symptoms worsened until REAC RGN-N therapy was introduced.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!